You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
廣生堂(300436.SZ):乙肝治療一類創新藥GST-HG131納入突破性治療品種名單
格隆匯 07-10 19:46

格隆匯7月10日丨廣生堂(300436.SZ)公佈,近日,福建廣生堂藥業股份有限公司創新藥控股子公司福建廣生中霖生物科技有限公司的乙肝治療一類創新藥GST-HG131,因“經加快上市申請專家論證會議定,本品為新機制治療藥物,現有數據提示具有明顯臨牀優勢”,被國家藥品監督管理局藥品審評中心(以下簡稱“藥審中心”)納入突破性治療品種名單。這是繼GST-HG141之後,公司在乙肝治療領域第二款獲得突破性治療認定的創新藥物。雙突破性治療認定的獲得,不僅驗證了公司在肝病治療領域的創新實力和藥物臨牀潛力,更為後續開展不同靶點聯合療法臨牀研究奠定了堅實基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account